Abstract:Systemic administration of immunomodulatory cytokines and antibodies (Ab) is often accompanied by serious toxicities that limit dosing and efficacy. Combining immune agonists can demonstrate synergistic enhancement of anti-tumor immunity, but exhibits further escalated toxicities; an example is co-treatment with interleukin-2 (IL-2) and agonistic antibodies for the T cell costimulatory receptor CD137 (αCD137). In order to reduce their in vivo toxicity and increase the therapeutic window, anti -CD137 and an engineered IL-2-Fc fusion protein were anchored on the surface of PEGylated liposomes (Lipo-αCD137/IL2-Fc) which served as a scaffold to deliver immunomodulatory antibodies systemically to mice bearing either primary melanoma or lung metastasis melanoma. In aggressive B16F10 melanoma model, combination treatment with αCD137 and IL-2-Fc (αCD137/IL2-Fc) suppressed tumor growth, but simultaneously induced lethal toxicity and all mice died within 6 days after repeated intravenous (IV) dosing. In striking contrast, Lipo-αCD137/IL2-Fc showed significant tumor growth inhibition without in vivo toxicity. αCD137/IL2-Fc induced dramatic elevation of systemic proinflammatory cytokines, but, little or undetectable amounts of proinflammatory cytokines were observed in Lipo-αCD137/IL2-Fc-treated animals. Lipo-αCD137/IL2-Fc enhanced the infiltration of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells in tumors and increased the CD8 to regulatory T cell ratio. In addition, immuno-liposome therapy triggered a significant production of IFN-γ in CTL upon ex vivo polyclonal stimulation, increased CTL proliferation and cytolytic degranulation in tumors and peripheral blood as evidenced by the enhanced expression of Ki67, CD107, and surface granzyme B. Mechanistically, Lipo-αCD137/IL2-Fc quickly entered tumors through their leaky vasculature but cleared from the blood rapidly following bolus IV administration, which allowed repetitive dosing of the immunoliposomes without systemic toxicity; while free αCD137 and IL2-Fc showed a prolonged blood circulation profile, which persistently activated circulating lymphocytes, leading to severe cytokine storm, vascular leak syndrome and decreased survival. Lipo-αCD137/IL2-Fc exhibited greatly increased accumulation in tumors at early time points compared to the free drugs, as observed by confocal imaging. αCD137/IL2-Fc also failed to elicit therapeutic efficacy in lung metastasis melanoma model, while Lipo-CD137/IL2-Fc showed superior antitumor immunity in both primary and metastasis melanoma models. In summary, we designed nanoparticle-IL-2/αCD137 formulations that rapidly accumulate in tumors while minimizing systemic exposure and preserving antitumor efficacy comparable to their soluble form. The improved biodistribution and pharmacokinetic profiles offered by the liposome scaffold contribute to the decreased toxicity. The liposome scaffold allows high density of Ab binding to their receptors and multivalent receptor engagement, leading to more effective T-cell stimulation. This strategy of hitchhiking immunomodulators on liposomes as a delivery vehicle makes the clinical in vivo application of therapeutic cytokines and immune agonists promising. Citation Format: Yuan Zhang, Darrell J. Irvine. Nanoparticle-mediated systemic delivery of immune agonists to tumors enabling anti-tumor efficacy without toxicity. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2016 Oct 20-23; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2017;5(3 Suppl):Abstract nr A87.

Systemic delivery of liposome-anchored anti-CD137 and IL2-Fc prevents lethal toxicity and elicits potent antitumor immunity

Abstract A87: Nanoparticle-mediated systemic delivery of immune agonists to tumors enabling anti-tumor efficacy without toxicity

Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity

Intratumoral delivery of liposome-anchored anti-CD137 and IL-2 induces highly potent local and systemic anti-tumor immunity while minimizing toxic inflammatory side effects

Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity

Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy

CD137, an attractive candidate for the immunotherapy of lung cancer.

Abstract 4058: Nanoparticle delivery of interleukin-2 induces anti-tumor immune response and therapeutic efficacy in mouse tumor models

Local delivery of cell surface-targeted immunocytokines programs systemic anti-tumor immunity

A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies

Intratumoral Delivery of IL-12 and IL-27 Mrna Using Lipid Nanoparticles for Cancer Immunotherapy.

Anti-PD-1 Cis-Delivery of Low-Affinity IL-12 Activates Intratumoral CD8+T Cells for Systemic Antitumor Responses.

Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

A Cytokine Receptor-Masked IL2 Prodrug Selectively Activates Tumor-Infiltrating Lymphocytes for Potent Antitumor Therapy

Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity

Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity

Abstract 5737: Enhancing cancer treatment Via a nanostructured chemoimmunotherapy gel facilitating interleukin-2 delivery and immunogenic cell death induction

Intravenous administration of IL-12 encoding self-replicating RNA-lipid nanoparticle complex leads to safe and effective antitumor responses

Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity

Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2

IL-2 targeted to CD8+ T cells promotes robust effector T cell responses and potent antitumor immunity